EGFR and neoplasm: The efficacy of in vivo tumour detection with anti-EGFR nanobody 99mTc-D10 was compared to the IgG199mTc-Cetuximab that was used to visualize A431 tumour lesions with comparable mean tumour volumes of 40 mm3 (N = 5; range 7–90 mm3) 45 min post injection.